Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04261543
Other study ID # MREC ID NO: 20181115-6890
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 5, 2019
Est. completion date March 1, 2025

Study information

Verified date May 2024
Source University of Malaya
Contact Zheng Yii Lee
Phone +60169754153
Email zheng_yii@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a 2-arm, parallel-group, randomized controlled trial that investigates the effect of combined high protein and early resistance exercise versus usual care on muscle mass, quality and strength, clinical outcomes, functional outcomes and quality of life in mechanically ventilated critically ill patients


Description:

With the advancement of critical care, about 80% of ICU patients are surviving critical illness. However, ICU survivors often experience significant post-ICU morbidities including muscle weakness and impairments in physical functioning that can persist for years. We hypothesized that early intervention with two of the most basic features of critical care: nutrition (feeding high protein) together with mobility (early resistance exercise) may help to attenuate muscle loss, thereby reducing the severity of ICU-acquired weakness and its associated physical impairments. A 2-arm, parallel-group, randomized controlled trial is proposed to investigate the effect of the combined interventions. The intervention will be conducted for up to 28 days in the ICU. Outcome measurements will be conducted by a blinded assessor at baseline (within 24 hours of randomization), Day 10 post-randomization, before hospital discharge and at 6-month post-randomization. Ultrasound and bioelectrical impedance analysis will be conducted to measure muscle mass and quality. Manual muscle testing, handgrip and knee extension strength will also be measured. Physical function will be assessed by a series of test including the six minutes walk test. Telephone interview will be conducted to administer quality of life questionnaires at 6 months. These combined simple and non-invasive interventions, if proven effective, may potentially revolutionize critical care.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date March 1, 2025
Est. primary completion date February 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: 1. Age 18 years old and above 2. Mechanically ventilated and expected to remain mechanically ventilated for an additional 48 hours from screening 3. High nutritional risk (at least one of the following): - BMI = 25 or = 35 - Moderate to severe malnutrition as defined by Subjective Global Assessment (SGA) - Frailty (Clinical Frailty Scale = 5 from proxy) - SARC-F (note: 'sarc-f' is the full name, not an abbreviation) questionnaire = 4 - From point of screening, projected duration of mechanical ventilation of >4 days Exclusion Criteria: 1. >96 continuous hours of mechanical ventilation before screening 2. Expected death or withdrawal of life-sustaining treatments within 7 days from screening 3. Pregnant (Note: post-partum and lactating patients are not excluded from the trial) 4. The responsible clinician feels that the patient either needs low or high protein 5. Patient requires parenteral nutrition only and site does not have products to reach the high protein dose group. 6. Not ambulating independently prior to illness that lead to ICU admission (use of gait aid permitted) 7. Lower extremity injury or impairments that prevents them walking prior to hospital discharge (e.g. amputation, knee/hip injury) 8. Pre-existing cognitive impairment or language barrier that prohibits outcomes assessment 9. Pre-existing primary severe systemic neuromuscular disease resulting in severe weakness pre-ICU (e.g., Guillain Barre) 10. Intracranial or spinal process affecting motor function 11. Patients in hospital >5 days prior to ICU admission 12. Not expected to stay =4 days after enrollment 13. Neuromuscular blocker infusion (eligible once infusion discontinued if other inclusion criteria met) 14. Lower extremity injury or impairments that prevents cycling (e.g. amputation, knee/hip injury) 15. Weight =150 kg 16. Physician declines enrolment for Exercise

Study Design


Related Conditions & MeSH terms


Intervention

Other:
High protein and early exercise
High protein is defined as protein prescription of =2.2 gram/kg body weight and early exercise is defined as starting cycle ergometry intervention within 24 hours of randomization
Usual Care
Usual care group has protein prescription of =1.2 gram/kg body weight and exercise at the discretion of attending clinicians

Locations

Country Name City State
Malaysia University of Malaya Kuala Lumpur

Sponsors (1)

Lead Sponsor Collaborator
University of Malaya

Country where clinical trial is conducted

Malaysia, 

References & Publications (3)

Arabi YM, Casaer MP, Chapman M, Heyland DK, Ichai C, Marik PE, Martindale RG, McClave SA, Preiser JC, Reignier J, Rice TW, Van den Berghe G, van Zanten ARH, Weijs PJM. The intensive care medicine research agenda in nutrition and metabolism. Intensive Care Med. 2017 Sep;43(9):1239-1256. doi: 10.1007/s00134-017-4711-6. Epub 2017 Apr 3. — View Citation

Herridge MS, Tansey CM, Matte A, Tomlinson G, Diaz-Granados N, Cooper A, Guest CB, Mazer CD, Mehta S, Stewart TE, Kudlow P, Cook D, Slutsky AS, Cheung AM; Canadian Critical Care Trials Group. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011 Apr 7;364(14):1293-304. doi: 10.1056/NEJMoa1011802. — View Citation

Heyland DK, Stapleton RD, Mourtzakis M, Hough CL, Morris P, Deutz NE, Colantuoni E, Day A, Prado CM, Needham DM. Combining nutrition and exercise to optimize survival and recovery from critical illness: Conceptual and methodological issues. Clin Nutr. 2016 Oct;35(5):1196-206. doi: 10.1016/j.clnu.2015.07.003. Epub 2015 Jul 16. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Rectus femoris cross-sectional area (RFCSA) RFCSA measured by ultrasonography Change in RFCSA between Day 1 and Day 10 of randomization
Primary Rectus femoris cross-sectional area (RFCSA) RFCSA measured by ultrasonography Change in RFCSA between Day 1 of randomization and within 72 hours before discharge from the hospital
Primary Rectus femoris linear depth (RF LD) RF LD measured by ultrasonography Change in RF LD between Day 1 and Day 10 of randomization
Primary Rectus femoris linear depth (RF LD) RF LD measured by ultrasonography Change in RF LD between Day 1 of randomization and within 72 hours before discharge from the hospital
Secondary Quadriceps muscle echogenicity Quadriceps muscle echogenicity measured by ultrasonography Day 1 and Day 10 of randomization, and within 72 hours before discharge from the hospital
Secondary Quadriceps muscle pennation angle Quadriceps muscle pennation angle measured by ultrasonography Day 1 and Day 10 of randomization, and within 72 hours before discharge from the hospital
Secondary Quadriceps muscle fascicle length Quadriceps muscle fascicle length measured by ultrasonography Day 1 and Day 10 of randomization, and within 72 hours before discharge from the hospital
Secondary Functional Status Score for the Intensive Care Unit (FSS-ICU) An assessment that consist of rolling, transfer from supine to sit, sitting at the edge of bed, transfer from sit to stand and walking Day 1 of randomization (surrogate interview), within 72 hours before discharge from the ICU and hospital (by trained physiotherapist)
Secondary Short Physical Performance Batteries (SPPB) An assessment that consist of balance test, gait speed test and chair stand test Within 72 hours before discharge from the ICU and hospital
Secondary Handgrip strength Handgrip strength of both hands by using handgrip dynamometer Within 72 hours before discharge from the ICU and hospital
Secondary 6 minutes walk test To evaluate how far the subject can walk in 6 minutes time Within 72 hours before discharge from the hospital
Secondary Manual muscle testing Bilateral muscle strength for shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension and ankle dorsiflexion Within 72 hours before discharge from the hospital
Secondary Knee extension strength Knee extension strength measured by Handheld Dynamometer Within 72 hours before discharge from the hospital
Secondary Mortality Percentage of patient who died Percentage of Patient who died within this ICU or hospital admission, at day 60 and 6 months post-randomization
Secondary Time-to-discharge alive from the hospital Time-to-discharge alive from the hospital Time elapsed from randomization to hospital discharge (for a maximum of 6 months from randomization)
Secondary Length of mechanical ventilation Duration of mechanical ventilation Total time from start to end of mechanical ventilation for a maximum of 6 months from randomization
Secondary Health-related Quality of life by 36-item short form survey (SF-36) SF-36 is a questionnaire that will be administered by telephone interview 6 months after randomization
Secondary Health-related Quality of life by Euro Quality of Life 5 Dimension 5 level (EQ-5D-5L) EQ-5D-5L is a questionnaire that will be administered by telephone interview 6 months after randomization
Secondary Katz Activities of Daily Living (ADL) Katz ADL is a questionnaire that will be administered by either surrogate or telephone interview Day 1 of randomization (surrogate interview) and 6 months after randomization (telephone interview)
Secondary Lawton Instrumental Activities of Daily Living (IADL) Lawton IADL is a questionnaire that will be administered by either surrogate or telephone interview Day 1 of randomization (surrogate interview) and 6 months after randomization (telephone interview)
See also
  Status Clinical Trial Phase
Completed NCT04551508 - Delirium Screening 3 Methods Study
Recruiting NCT06037928 - Plasma Sodium and Sodium Administration in the ICU
Completed NCT03671447 - Enhanced Recovery After Intensive Care (ERIC) N/A
Recruiting NCT03941002 - Continuous Evaluation of Diaphragm Function N/A
Recruiting NCT04674657 - Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
Completed NCT04239209 - Effect of Intensivist Communication on Surrogate Prognosis Interpretation N/A
Completed NCT05531305 - Longitudinal Changes in Muscle Mass After Intensive Care N/A
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Completed NCT02916004 - The Use of Nociception Flexion Reflex and Pupillary Dilatation Reflex in ICU Patients. N/A
Recruiting NCT05883137 - High-flow Nasal Oxygenation for Apnoeic Oxygenation During Intubation of the Critically Ill
Completed NCT04479254 - The Impact of IC-Guided Feeding Protocol on Clinical Outcomes in Critically Ill Patients (The IC-Study) N/A
Recruiting NCT04475666 - Replacing Protein Via Enteral Nutrition in Critically Ill Patients N/A
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Not yet recruiting NCT04538469 - Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
Withdrawn NCT04043091 - Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction N/A
Recruiting NCT02922998 - CD64 and Antibiotics in Human Sepsis N/A
Recruiting NCT02989051 - Fluid Restriction Keeps Children Dry Phase 2/Phase 3
Completed NCT02899208 - Can an Actigraph be Used to Predict Physical Function in Intensive Care Patients? N/A
Completed NCT03048487 - Protein Consumption in Critically Ill Patients
Recruiting NCT02163109 - Oxygen Consumption in Critical Illness